McBeath Health Services joins Slade Health facilities in NSW
Slade Health (as part of the Icon Consolidated Holdings) has entered into an agreement with McBeath Health Service to re-locate their oncology compounding business to the Slade Health TGA facilities based at Mt Kuring-gai NSW.
The business will also include the pharmacy dispensing services currently offered by McBeath which will become part of the Pharmatel Oncology Dispensary.
McBeath Health Services currently supplies hospital and day oncology centres across NSW and ACT with sterile compounded products and also facilitates the management of PBS prescriptions.
The closing of this transaction is anticipated in Q2/2016. There will be a transition period and hand over to Slade Health which will ensure continuous high quality supply and no disruption to patients treatments.
According to Slade Managing Director, David Slade, this furthers expands the Slade Health capabilities and presence in the sterile TGA compounding market across the east coast.
“This is an exciting time and great opportunity for Slade”, David said. “McBeath has a strong presence in the NSW/ACT market and significant customer relationships. The McBeath business has great experience in chemotherapy supply and the management of PBS scripting to hospitals. We look forward to welcoming Adrian Wilson to our team.”
The McBeath merger follows the Slade acquisition of the Fresenius Kabi compounding facilities in October which increased the Slade Health TGA licenced facilities to four across Australia.